BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 20492324)

  • 1. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of NASH: getting both pathology and metabolic context right.
    Larter CZ; Yeh MM
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1635-48. PubMed ID: 18752564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
    Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.
    Cusi K
    Clin Liver Dis; 2009 Nov; 13(4):545-63. PubMed ID: 19818304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic steatohepatitis and metabolic syndrome.
    Machado M; Cortez-Pinto H
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
    Cusi K
    Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and steatosis in humans.
    Capeau J
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):649-57. PubMed ID: 19195626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver fibrogenesis and metabolic factors.
    Anty R; Lemoine M
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S10-20. PubMed ID: 21742296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Zavos C; Tsiaousi E
    Diabetes Obes Metab; 2010 May; 12(5):365-83. PubMed ID: 20415685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent concepts in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Diabet Med; 2005 Sep; 22(9):1129-33. PubMed ID: 16108837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver: role of inflammation and fatty acid nutrition.
    Byrne CD
    Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.